1 |
BOCCANEGRA B, CAPPELLARI O, MANTUANO P, et al. Growth hormone secretagogues modulate inflammation and fibrosis in mdx mouse model of Duchenne muscular dystrophy[J]. Front Immunol, 2023, 14:1119888. DOI: 10.3389/fimmu.2023.1119888 .
|
2 |
JAXYBAYEVA A, CHUNKAYEVA D, MYRZALIYEVA B, et al. Duchenne muscular dystrophy in Kazakhstan: a journey from diagnosis to the treatment, the biases and achievements[J]. J Neuromuscul Dis, 2023, 10(2):263-269. DOI: 10.3233/JND-221559 .
|
3 |
RICCI G, BELLO L, TORRI F, et al. Therapeutic opportunities and clinical outcome measures in Duchenne muscular dystrophy[J]. Neurol Sci, 2022, 43():625-633. DOI: 10.1007/s10072-022-06085-w .
|
4 |
FISCHER R, PORTER K, DONOVAN J M, et al. A mixed-method study exploring patient-experienced and caregiver-reported benefits and side effects of corticosteroid use in Duchenne muscular dystrophy[J]. J Neuromuscul Dis, 2023, 10(4):593-613. DOI: 10.3233/JND-221617 .
|
5 |
DEN HARTOG L, ASAKURA A. Implications of Notch signaling in Duchenne muscular dystrophy[J]. Front Physiol, 2022, 13:984373. DOI: 10.3389/fphys.2022.984373 .
|
6 |
KODIPPILI K, RUDNICKI M A. Satellite cell contribution to disease pathology in Duchenne muscular dystrophy[J]. Front Physiol, 2023, 14:1180980. DOI: 10.3389/fphys.2023.1180980 .
|
7 |
SAIFULLAH, MOTOHASHI N, TSUKAHARA T, et al. Development of therapeutic RNA manipulation for muscular dystrophy[J]. Front Genome Ed, 2022, 4:863651. DOI: 10.3389/fgeed.2022.863651 .
|
8 |
MIN Y L, BASSEL-DUBY R, OLSON E N. CRISPR correction of Duchenne muscular dystrophy[J]. Annu Rev Med, 2019, 70:239-255. DOI: 10.1146/annurev-med-081117-010451 .
|
9 |
OLSON E N. Toward the correction of muscular dystrophy by gene editing[J]. Proc Natl Acad Sci U S A, 2021, 118(22): e2004840117. DOI: 10.1073/pnas.2004840117 .
|
10 |
AARTSMA-RUS A, DE WAELE L, HOUWEN-OPSTAL S, et al. The dilemma of choice for Duchenne patients eligible for exon 51 skipping the European experience[J]. J Neuromuscul Dis, 2023, 10(3):315-325. DOI: 10.3233/JND-221648 .
|
11 |
MAMSA H, STARK R L, SHIN K M, et al. Sarcospan increases laminin-binding capacity of α-dystroglycan to ameliorate DMD independent of Galgt2[J]. Hum Mol Genet, 2022, 31(5):718-732. DOI: 10.1093/hmg/ddab276 .
|
12 |
REID A L, ALEXANDER M S. The interplay of mitophagy and inflammation in Duchenne muscular dystrophy[J]. Life (Basel), 2021, 11(7):648. DOI: 10.3390/life11070648 .
|
13 |
KAMDAR F, GARRY D J. Dystrophin-deficient cardiomyopathy[J]. J Am Coll Cardiol, 2016, 67(21):2533-2546. DOI: 10.1016/j.jacc.2016.02.081 .
|
14 |
MANINI A, ABATI E, NUREDINI A, et al. Adeno-associated virus (AAV)-mediated gene therapy for Duchenne muscular dystrophy: the issue of transgene persistence[J]. Front Neurol, 2021, 12:814174. DOI: 10.3389/fneur.2021.814174 .
|
15 |
NOVAK J S, SPATHIS R, DANG U J, et al. Interrogation of dystrophin and dystroglycan complex protein turnover after exon skipping therapy[J]. J Neuromuscul Dis, 2021, 8(s2): S383-S402. DOI: 10.3233/JND-210696 .
|
16 |
FRANK D E, SCHNELL F J, AKANA C, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy[J]. Neurology, 2020, 94(21): e2270-e2282. DOI: 10.1212/WNL.0000000000009233 .
|
17 |
SHIRLEY M. Casimersen: first approval[J]. Drugs, 2021, 81(7):875-879. DOI: 10.1007/s40265-021-01512-2 .
|
18 |
WILTON-CLARK H, YOKOTA T. Casimersen for Duchenne muscular dystrophy[J]. Drugs Today, 2021, 57(12):707-717. DOI: 10.1358/dot.2021.57.12.3352740 .
|
19 |
HU G, CHEN C. Promising treatments for Duchenne muscular dystrophy: restoring dystrophin protein expression using nucleic acid therapeutics[J]. Int J Drug Discov Pharmacol, 2023: n.pag. DOI: 10.53941/ijddp.0201002 .
|
20 |
SAZANI P, WELLER D L, SHREWSBURY S B. Safety pharmacology and genotoxicity evaluation of AVI-4658[J]. Int J Toxicol, 2010, 29(2):143-156. DOI: 10.1177/1091581809359206 .
|
21 |
SAZANI P, NESS K P, WELLER D L, et al. Chemical and mechanistic toxicology evaluation of exon skipping phosphorodiamidate morpholino oligomers in mdx mice[J]. Int J Toxicol, 2011, 30(3):322-333. DOI: 10.1177/1091581811403504 .
|
22 |
HAPPI MBAKAM C, LAMOTHE G, TREMBLAY J P. Therapeutic strategies for dystrophin replacement in Duchenne muscular dystrophy[J]. Front Med, 2022, 9:859930. DOI: 10.3389/fmed.2022.859930 .
|
23 |
STIMPSON G, RAQUQ S, CHESSHYRE M, et al. Growth pattern trajectories in boys with Duchenne muscular dystrophy[J]. Orphanet J Rare Dis, 2022, 17(1):20. DOI: 10.1186/s13023-021-02158-9 .
|
24 |
MENDELL J R, RODINO-KLAPAC L R, SAHENK Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy[J]. Ann Neurol, 2013, 74(5):637-647. DOI: 10.1002/ana.23982 .
|
25 |
ALFANO L N, CHARLESTON J S, CONNOLLY A M, et al. Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy[J]. Medicine, 2019, 98(26): e15858. DOI: 10.1097/MD.0000000000015858 .
|
26 |
TRAYNOR K. Eteplirsen approved for Duchenne muscular dystrophy[J]. Am J Health Syst Pharm, 2016, 73(21):1719. DOI: 10.2146/news160063 .
|
27 |
AARTSMA-RUS A, KRIEG A M. FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen Saga[J]. Nucleic Acid Ther, 2017, 27(1):1-3. DOI: 10.1089/nat.2016.0657 .
|
28 |
MCDONALD C M, SHIEH P B, ABDEL-HAMID H Z, et al. Open-label evaluation of eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI trial[J]. J Neuromuscul Dis, 2021, 8(6):989-1001. DOI: 10.3233/JND-210643 .
|
29 |
ECHIGOYA Y, LIM K R Q, TRIEU N, et al. Quantitative antisense screening and optimization for exon 51 skipping in Duchenne muscular dystrophy[J]. Mol Ther, 2017, 25(11):2561-2572. DOI: 10.1016/j.ymthe.2017.07.014 .
|
30 |
ANWAR S, YOKOTA T. Golodirsen for Duchenne muscular dystrophy[J]. Drugs Today, 2020, 56(8):491-504. DOI: 10.1358/dot.2020.56.8.3159186 .
|
31 |
Anon. Abstracts of the 12th UK neuromuscular translational research conference, 4th and 5th April 20191[J]. J Neuromuscul Dis, 2019, 6(s1): S1-S109. DOI: 10.3233/JND-190000 .
|
32 |
SERVAIS L, MERCURI E, STRAUB V, et al. Long-term safety and efficacy data of golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1/2 trial[J]. Nucleic Acid Ther, 2022, 32(1):29-39. DOI: 10.1089/nat.2021.0043 .
|
33 |
AARTSMA-RUS A, COREY D R. The 10th oligonucleotide therapy approved: golodirsen for Duchenne muscular dystrophy[J]. Nucleic Acid Ther, 2020, 30(2):67-70. DOI: 10.1089/nat.2020.0845 .
|
34 |
ASSEFA M, GEPFERT A, ZAHEER M, et al. Casimersen (AMONDYS 45™): an antisense oligonucleotide for Duchenne muscular dystrophy[J]. Biomedicines, 2024, 12(4):912. DOI: 10.3390/biomedicines12040912 .
|
35 |
VASTERLING M E, MAITSKI R J, DAVIS B A, et al. AMONDYS 45 (casimersen), a novel antisense phosphorodiamidate morpholino oligomer: clinical considerations for treatment in Duchenne muscular dystrophy[J]. Cureus, 2023, 15(12): e51237. DOI: 10.7759/cureus.51237 .
|
36 |
CLEMENS P R, RAO V K, CONNOLLY A M, et al. Long-term functional efficacy and safety of viltolarsen in patients with Duchenne muscular dystrophy[J]. J Neuromuscul Dis, 2022, 9(4):493-501. DOI: 10.3233/JND-220811 .
|
37 |
COHEN S A, BAR-AM O, FUOCO C, et al. In vivo restoration of dystrophin expression in mdx mice using intra-muscular and intra-arterial injections of hydrogel microsphere carriers of exon skipping antisense oligonucleotides[J]. Cell Death Dis, 2022, 13(9):779. DOI: 10.1038/s41419-022-05166-0 .
|
38 |
POLITANO L. Read-through approach for stop mutations in Duchenne muscular dystrophy. An update[J]. Acta Myol, 2021, 40(1):43-50. DOI: 10.36185/2532-1900-041 .
|
39 |
刘延波, 徐乃军, 贾飞勇. Duchenne肌营养不良(DMD)发病机制及治疗研究进展[J]. 生命科学, 2012, 24(4):354-361.
|
|
LIU Y B, XU N J, JIA F Y. The research progresses of Duchenne muscular dystrophy (DMD) in it's pathogenesis and therapy[J]. Chin Bull Life Sci, 2012, 24(4):354-361.
|
40 |
MICHOROWSKA S. Ataluren-promising therapeutic premature termination Codon readthrough frontrunner[J]. Pharmaceuticals, 2021, 14(8):785. DOI: 10.3390/ph14080785 .
|
41 |
CAMPBELL C, BAROHN R J, BERTINI E, et al. Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy[J]. J Comp Eff Res, 2020, 9(14):973-984. DOI: 10.2217/cer-2020-0095 .
|
42 |
MUNTONI F, DESGUERRE I, GUGLIERI M, et al. Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE registry[J]. J Comp Eff Res, 2019, 8(14):1187-1200. DOI: 10.2217/cer-2019-0086 .
|
43 |
MERCURI E, MUNTONI F, OSORIO A N, et al. Safety and effectiveness of ataluren: comparison of results from the STRIDE registry and CINRG DMD natural history study[J]. J Comp Eff Res, 2020, 9(5):341-360. DOI: 10.2217/cer-2019-0171 .
|
44 |
FONTELONGA T M, JORDAN B, NUNES A M, et al. Sunitinib promotes myogenic regeneration and mitigates disease progression in the mdx mouse model of Duchenne muscular dystrophy[J]. Hum Mol Genet, 2019, 28(13):2120-2132. DOI: 10.1093/hmg/ddz044 .
|
45 |
SIRBU C A, IVAN R, AUTHIER F J, et al. Orphan drugs in neurology-a narrative review[J]. J Pers Med, 2023, 13(3):420. DOI: 10.3390/jpm13030420 .
|
46 |
SHEIKH O, YOKOTA T. Advances in genetic characterization and genotype-phenotype correlation of Duchenne and Becker muscular dystrophy in the personalized medicine era[J]. J Pers Med, 2020, 10(3):111. DOI: 10.3390/jpm10030111 .
|
47 |
COLLOTTA D, BERTOCCHI I, CHIAPELLO E, et al. Antisense oligonucleotides: a novel Frontier in pharmacological strategy[J]. Front Pharmacol, 2023, 14:1304342. DOI: 10.3389/fphar.2023.1304342 .
|
48 |
BIRCH S M, LAWLOR M W, CONLON T J, et al. Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy[J]. Sci Transl Med, 2023, 15(677): eabo1815. DOI: 10.1126/scitranslmed.abo1815 .
|
49 |
ALBINI S, PALMIERI L, DUBOIS A, et al. Assessment of therapeutic potential of a dual AAV approach for Duchenne muscular dystrophy[J]. Int J Mol Sci, 2023, 24(14):11421. DOI: 10.3390/ijms241411421 .
|
50 |
LONG C Z, AMOASII L, MIREAULT A A, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy[J]. Science, 2016, 351(6271):400-403. DOI: 10.1126/science.aad5725 .
|
51 |
TABEBORDBAR M, ZHU K X, CHENG J K W, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells[J]. Science, 2016, 351(6271):407-411. DOI: 10.1126/science.aad5177 .
|
52 |
NELSON C E, HAKIM C H, OUSTEROUT D G, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy[J]. Science, 2016, 351(6271):403-407. DOI: 10.1126/science.aad5143 .
|
53 |
KUPATT C, WINDISCH A, MORETTI A, et al. Genome editing for Duchenne muscular dystrophy: a glimpse of the future?[J]. Gene Ther, 2021, 28(9):542-548. DOI: 10.1038/s41434-021-00222-4 .
|
54 |
AMOASII L, HILDYARD JCW, LI H, et al. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy[J]. Science, 2018, 362(6410): 86-91.DOI:10.1126/science.aau1549 .
|
55 |
MORETTI A, FONTEYNE L, GIESERT F, et al. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy[J]. Nat Med, 2020,26(2): 207-214. DOI: 10.1038/s41591-019-0738-2 .
|
56 |
LEK A, WONG B, KEELER A, et al. Unexpected death of a Duchenne muscular dystrophy patient in an N-of-1 trial of rAAV9-delivered CRISPR-transactivator[R/OL]. medRxiv (Preprint), 2023.(2023-05-30)[2024-12-01]. . DOI: 10.1101/2023.05.16.23289881 .
|
57 |
REN S W, FU X, GUO W T, et al. Profound cellular defects attribute to muscular pathogenesis in the Rhesus monkey model of Duchenne muscular dystrophy[J]. Cell, 2024, 187(23):6669-6686.e16. DOI: 10.1016/j.cell.2024.08.041 .
|